Novartis Historical Balance Sheet

NVS Stock

USD 103.85 0.76 0.74%

Trend analysis of Novartis AG ADR balance sheet accounts such as Total Current Liabilities of 22 B provides information on Novartis' total assets, liabilities, and equity, which is the actual value of Novartis AG ADR to its prevalent stockholders. By breaking down trends over time using Novartis balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Novartis AG ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novartis AG ADR is a good buy for the upcoming year.

Novartis Inventory

5.95 Billion

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

About Novartis Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Novartis AG ADR at a specified time, usually calculated after every quarter, six months, or one year. Novartis Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Novartis and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Novartis currently owns. An asset can also be divided into two categories, current and non-current.

Novartis Balance Sheet Chart

At this time, Novartis' Inventory is comparatively stable compared to the past year. Other Assets is likely to gain to about 10.1 B in 2024, whereas Other Current Liabilities is likely to drop slightly above 11 B in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Novartis assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Novartis AG ADR books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Novartis balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Novartis AG ADR are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Novartis' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	31.1B	28.0B	26.3B	18.6B
Total Assets	131.8B	117.5B	99.9B	103.1B

Short Long Term Debt Total Total Assets

Novartis balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Capital Stock
Total Assets		0.71	0.8	0.78	0.92	0.78	0.52	0.71	0.92	0.92	0.29	0.97	-0.28	0.12	0.77	-0.07	-0.26	-0.01	0.89	0.77	-0.14	-0.52	0.88	0.43	0.41	-0.07
Short Long Term Debt Total	0.71		0.82	0.88	0.39	0.18	0.17	0.9	0.44	0.63	0.58	0.63	0.29	0.42	0.42	-0.4	-0.47	0.18	0.91	0.64	0.0	0.05	0.94	0.22	0.5	-0.4
Other Current Liab	0.8	0.82		0.96	0.56	0.42	0.2	0.68	0.58	0.86	0.58	0.66	-0.1	0.46	0.46	-0.28	-0.42	0.23	0.81	0.71	0.23	-0.11	0.91	0.32	0.7	-0.3
Total Current Liabilities	0.78	0.88	0.96		0.5	0.36	0.11	0.75	0.52	0.83	0.58	0.66	-0.03	0.46	0.44	-0.36	-0.47	0.21	0.84	0.74	0.27	-0.01	0.94	0.34	0.66	-0.37
Total Stockholder Equity	0.92	0.39	0.56	0.5		0.9	0.65	0.43	0.99	0.83	0.07	0.92	-0.46	-0.05	0.78	0.12	-0.08	-0.08	0.66	0.65	-0.26	-0.72	0.62	0.42	0.26	0.12
Property Plant And Equipment Net	0.78	0.18	0.42	0.36	0.9		0.46	0.28	0.85	0.76	-0.12	0.84	-0.63	-0.34	0.77	0.29	0.09	-0.33	0.53	0.59	-0.21	-0.81	0.48	0.45	0.02	0.3
Current Deferred Revenue	0.52	0.17	0.2	0.11	0.65	0.46		0.12	0.69	0.35	0.17	0.55	-0.36	-0.12	0.23	0.1	0.01	-0.26	0.33	0.12	-0.33	-0.59	0.26	0.23	0.04	0.1
Net Debt	0.71	0.9	0.68	0.75	0.43	0.28	0.12		0.47	0.61	0.17	0.7	0.22	0.16	0.55	-0.25	-0.37	0.14	0.9	0.68	-0.1	-0.02	0.88	0.11	0.23	-0.25
Retained Earnings	0.92	0.44	0.58	0.52	0.99	0.85	0.69	0.47		0.82	0.12	0.92	-0.41	-0.01	0.75	0.08	-0.12	-0.06	0.69	0.64	-0.28	-0.7	0.65	0.42	0.28	0.08
Accounts Payable	0.92	0.63	0.86	0.83	0.83	0.76	0.35	0.61	0.82		0.29	0.88	-0.41	0.11	0.66	-0.12	-0.31	-0.01	0.79	0.76	0.14	-0.45	0.84	0.59	0.43	-0.12
Cash	0.29	0.58	0.58	0.58	0.07	-0.12	0.17	0.17	0.12	0.29		0.11	0.25	0.66	-0.08	-0.45	-0.37	0.13	0.38	0.17	0.19	0.15	0.48	0.28	0.71	-0.44
Non Current Assets Total	0.97	0.63	0.66	0.66	0.92	0.84	0.55	0.7	0.92	0.88	0.11		-0.33	-0.13	0.8	0.02	-0.17	-0.2	0.87	0.71	-0.23	-0.64	0.82	0.46	0.16	0.03
Non Currrent Assets Other	-0.28	0.29	-0.1	-0.03	-0.46	-0.63	-0.36	0.22	-0.41	-0.41	0.25	-0.33		0.39	-0.07	-0.49	-0.41	0.26	0.01	-0.19	-0.34	0.58	0.0	-0.29	0.12	-0.5
Cash And Short Term Investments	0.12	0.42	0.46	0.46	-0.05	-0.34	-0.12	0.16	-0.01	0.11	0.66	-0.13	0.39		-0.16	-0.45	-0.41	0.81	0.15	0.25	0.3	0.54	0.29	-0.17	0.91	-0.49
Net Receivables	0.77	0.42	0.46	0.44	0.78	0.77	0.23	0.55	0.75	0.66	-0.08	0.8	-0.07	-0.16		0.07	-0.17	-0.13	0.65	0.59	-0.54	-0.57	0.59	0.34	0.11	0.07
Common Stock Total Equity	-0.07	-0.4	-0.28	-0.36	0.12	0.29	0.1	-0.25	0.08	-0.12	-0.45	0.02	-0.49	-0.45	0.07		0.96	-0.06	-0.2	-0.09	-0.24	-0.57	-0.28	-0.25	-0.35	1.0
Common Stock Shares Outstanding	-0.26	-0.47	-0.42	-0.47	-0.08	0.09	0.01	-0.37	-0.12	-0.31	-0.37	-0.17	-0.41	-0.41	-0.17	0.96		-0.07	-0.33	-0.22	-0.14	-0.43	-0.4	-0.31	-0.38	0.96
Short Term Investments	-0.01	0.18	0.23	0.21	-0.08	-0.33	-0.26	0.14	-0.06	-0.01	0.13	-0.2	0.26	0.81	-0.13	-0.06	-0.07		-0.02	0.25	0.25	0.49	0.07	-0.42	0.67	-0.13
Non Current Liabilities Total	0.89	0.91	0.81	0.84	0.66	0.53	0.33	0.9	0.69	0.79	0.38	0.87	0.01	0.15	0.65	-0.2	-0.33	-0.02		0.7	-0.14	-0.29	0.97	0.32	0.35	-0.19
Inventory	0.77	0.64	0.71	0.74	0.65	0.59	0.12	0.68	0.64	0.76	0.17	0.71	-0.19	0.25	0.59	-0.09	-0.22	0.25	0.7		0.14	-0.19	0.75	0.27	0.47	-0.11
Other Current Assets	-0.14	0.0	0.23	0.27	-0.26	-0.21	-0.33	-0.1	-0.28	0.14	0.19	-0.23	-0.34	0.3	-0.54	-0.24	-0.14	0.25	-0.14	0.14		0.42	0.02	0.12	0.28	-0.25
Other Stockholder Equity	-0.52	0.05	-0.11	-0.01	-0.72	-0.81	-0.59	-0.02	-0.7	-0.45	0.15	-0.64	0.58	0.54	-0.57	-0.57	-0.43	0.49	-0.29	-0.19	0.42		-0.18	-0.33	0.25	-0.59
Total Liab	0.88	0.94	0.91	0.94	0.62	0.48	0.26	0.88	0.65	0.84	0.48	0.82	0.0	0.29	0.59	-0.28	-0.4	0.07	0.97	0.75	0.02	-0.18		0.34	0.49	-0.27
Property Plant And Equipment Gross	0.43	0.22	0.32	0.34	0.42	0.45	0.23	0.11	0.42	0.59	0.28	0.46	-0.29	-0.17	0.34	-0.25	-0.31	-0.42	0.32	0.27	0.12	-0.33	0.34		0.02	-0.21
Total Current Assets	0.41	0.5	0.7	0.66	0.26	0.02	0.04	0.23	0.28	0.43	0.71	0.16	0.12	0.91	0.11	-0.35	-0.38	0.67	0.35	0.47	0.28	0.25	0.49	0.02		-0.38
Capital Stock	-0.07	-0.4	-0.3	-0.37	0.12	0.3	0.1	-0.25	0.08	-0.12	-0.44	0.03	-0.5	-0.49	0.07	1.0	0.96	-0.13	-0.19	-0.11	-0.25	-0.59	-0.27	-0.21	-0.38

Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	118.4B	132.1B	131.8B	117.5B	99.9B	103.1B
Short Long Term Debt Total	29.3B	38.0B	31.1B	28.0B	26.3B	18.6B
Other Current Liab	15.4B	15.1B	15.5B	14.7B	12.6B	11.0B
Total Current Liabilities	28.3B	33.1B	30.2B	28.7B	26.4B	22.0B
Total Stockholder Equity	55.5B	56.6B	67.7B	59.3B	46.7B	57.2B
Property Plant And Equipment Net	13.7B	13.9B	13.1B	12.2B	10.9B	13.5B
Current Deferred Revenue	236M	114M	56M	123M	98M	135.9M
Net Debt	18.2B	28.4B	18.7B	20.4B	13.0B	11.0B
Retained Earnings	59.3B	57.2B	71.0B	63.5B	49.6B	58.0B
Accounts Payable	5.4B	5.4B	5.6B	5.1B	4.9B	4.2B
Cash	11.1B	9.7B	12.4B	7.5B	13.4B	7.7B
Non Current Assets Total	88.9B	102.4B	86.1B	80.5B	69.5B	73.2B
Non Currrent Assets Other	738M	892M	2.2B	1.1B	2.2B	2.1B
Cash And Short Term Investments	11.4B	11.6B	28.3B	18.9B	14.4B	13.1B
Net Receivables	8.6B	9.1B	8.8B	8.9B	7.1B	8.8B
Common Stock Total Equity	969M	944M	936M	913M	821.7M	776.8M
Common Stock Shares Outstanding	2.3B	2.3B	2.3B	2.2B	2.1B	1.9B
Short Term Investments	334M	1.9B	15.9B	11.4B	680M	646M
Liabilities And Stockholders Equity	118.4B	132.1B	131.8B	117.5B	99.9B	103.1B
Non Current Liabilities Total	34.6B	42.3B	33.8B	29.4B	26.8B	23.6B
Inventory	6.0B	7.1B	6.7B	7.2B	5.9B	6.0B
Other Current Assets	2.7B	2.9B	2.8B	2.9B	3.4B	2.3B
Other Stockholder Equity	(59.4B)	(53M)	(48M)	(92M)	(41M)	(43.1M)
Total Liab	62.8B	75.4B	64.0B	58.0B	53.2B	45.6B
Property Plant And Equipment Gross	13.7B	13.9B	13.1B	12.2B	22.8B	14.0B
Total Current Assets	29.5B	29.7B	45.7B	36.9B	30.5B	29.9B
Capital Stock	936M	913M	901M	890M	825M	767.6M
Short Term Debt	7.3B	10.1B	6.6B	6.2B	6.3B	6.3B
Common Stock	936M	913M	901M	890M	825M	767.6M
Accumulated Other Comprehensive Income	54.6B	55.7B	66.8B	58.5B	(3.8B)	(3.6B)
Intangible Assets	28.8B	36.8B	34.2B	31.6B	26.9B	22.4B
Other Liab	12.5B	14.4B	9.2B	7.6B	8.7B	8.5B
Other Assets	14.8B	14.7B	12.4B	4.8B	5.6B	10.1B
Long Term Debt	20.4B	26.3B	22.9B	20.2B	18.4B	12.8B
Good Will	26.5B	30.0B	29.6B	29.3B	23.3B	22.0B
Treasury Stock	(69M)	(80M)	(53M)	(48M)	(41M)	(43.1M)
Property Plant Equipment	13.7B	13.9B	13.1B	12.2B	14.0B	14.0B
Net Tangible Assets	5.6B	(5.5B)	9.4B	2.8B	2.5B	2.4B
Noncontrolling Interest In Consolidated Entity	77M	68M	167M	81M	83M	93.5M
Deferred Long Term Liab	5.4B	4.7B	5.5B	4.4B	5.1B	5.8B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novartis Historical Balance Sheet

Novartis Inventory

5.95 Billion

About Novartis Balance Sheet Analysis

Novartis Balance Sheet Chart

Total Assets

Total Current Liabilities

Novartis balance sheet Correlations

Novartis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novartis balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Novartis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Stock	+ 1.0	Common Stock Total Equity
Retained Earnings	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.97	Total Assets
Total Liab	+ 0.97	Non Current Liabilities Total
Total Current Liabilities	+ 0.96	Other Current Liab
Common Stock Shares Outstanding	+ 0.96	Common Stock Total Equity

Other Stockholder Equity	- 0.81	Property Plant And Equipment Net
Other Stockholder Equity	- 0.72	Total Stockholder Equity
Other Stockholder Equity	- 0.7	Retained Earnings
Other Stockholder Equity	- 0.64	Non Current Assets Total
Non Currrent Assets Other	- 0.63	Property Plant And Equipment Net
Capital Stock	- 0.59	Other Stockholder Equity